Acrux Limited (ASX: ACR), the Australian pharmaceutical company that specialises in products delivering therapeutic drugs through the skin, today announced that it has been granted four more US patents relating to its transdermal drug delivery technology. The four US patents provide additional protection for systemic delivery of drugs in specific therapeutic areas, namely analgesics (US patent number 6,916,486), hormones (6,923,983), anti-Parkinson's agents (6,929,801) and anti-emetics (6,916,487). These are "continuation in part" patents, related to Acrux's US patent number 6,818,226.
The new patents, which expire in February 2017, further extend the proprietary nature of Acrux's transdermal drug delivery technology for a number of products in the current pipeline. They provide protection for transdermal drug delivery systems, in the specific therapy areas, that consist of an effective amount of physiologically active agent (e.g. a therapeutic drug), a dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen, and a volatile liquid. Acrux now has six patents granted in the USA.
Acrux CEO and Managing Director, Dr Igor Gonda said: "These new US patents provide additional protection for our products in our core areas of interest. Our patenting activity is at the heart of our business strategy to develop and commercialise patient-preferred patent-protected healthcare products for valuable global markets."
Page: 1 Related medicine news :1
Contact: Igor Gonda
. REVLIMID(R) granted approval by FDA for treatment of multiple myeloma2
. Acrux granted first grant in Europe, triggering payment from Lilly3
. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug4
. Acrux completes enrollment in key phase 2 trial5
. Acrux and Oreganon further expand their collaboration6
. Acrux patent portfolio advances in USA7
. Acrux acquires rights to commercialise worlds first contraceptive spray8
. Acrux reports progress in development of Testosterone MD-Lotion(R) for men9
. DAYTRANA (methylphenidate transdermal system) significant reduces ADHD symptoms10
. Shires DAYTRANA(TM) transdermal patch approved by FDA for treatment of ADHD11
. Positive study results for methylphenidate transdermal system